BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment Pharmacol Ther. 2007;25:511-517. [PMID: 17270007 DOI: 10.1111/j.1365-2036.2006.03196.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Wu JC. Is longer duration of proton pump inhibitor trial better for gastroesophageal reflux disease-related non-cardiac chest pain? Journal of Gastroenterology and Hepatology 2009;24:1477-8. [DOI: 10.1111/j.1440-1746.2009.05983.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
3 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 8.9] [Reference Citation Analysis]
4 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kantas I, Balatsouras DG, Kamargianis N, Katotomichelakis M, Riga M, Danielidis V. The influence of laryngopharyngeal reflux in the healing of laryngeal trauma. Eur Arch Otorhinolaryngol 2009;266:253-9. [DOI: 10.1007/s00405-008-0744-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
6 Duman M, Özer M, Reyhan E, Demirci Y, Atıcı AE, Dalgıç T, Bostancı EB, Genç E. In vitro effect of pantoprazole on lower esophageal sphincter tone in rats. World J Gastroenterol 2011; 17(46): 5105-5109 [PMID: 22171145 DOI: 10.3748/wjg.v17.i46.5105] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;CD004275. [PMID: 19821323 DOI: 10.1002/14651858.cd004275.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
9 Fass R. The relationship between gastroesophageal reflux disease and sleep. Curr Gastroenterol Rep 2009;11:202-8. [DOI: 10.1007/s11894-009-0032-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
10 Shin JS, Lee JY, Cho KH, Park HL, Kukulka M, Wu JT, Kim DY, Park SH. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. Aliment Pharmacol Ther 2014;40:548-61. [PMID: 25041486 DOI: 10.1111/apt.12860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]